BUSINESS

Zytiga Gets Priority Review Status for Earlier Use in Prostate Cancer

October 11, 2017

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Janssen Pharmaceutical said on October 10 that the Japanese health ministry granted its prostate cancer drug Zytiga (abiraterone) a priority review status for an additional indication of hormone therapy-naïve patients with metastatic prostate cancer.In Japan, Zytiga was approved in July…

To read the full story

Zytiga Shows Consistent Efficacy in Japanese High-Risk mHNPC Patients
February 14, 2018
Zytiga Filed for Earlier Prostate Cancer Treatment
May 29, 2017

BUSINESS

Ultragenyx Seeks Japan Approval for GSDIa Gene Therapy
July 1, 2026
Specialist Hails Wegovy as “Game Changer” for MASH Treatment
July 1, 2026
Alfresa Boosts Stake in ENT Cell Sheet Startup
July 1, 2026
Eisai, UCL Renew Neuroscience Alliance to 2030
July 1, 2026
Asahi Kasei Nabs Japan Rights to Additional Empaveli Indications
July 1, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard

By Philip Carrigan

Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…